PMID: 26767428Jan 16, 2016Paper

The Structure-Activity Relationship of Glycosaminoglycans and Their Analogues with β-Amyloid Peptide

Protein and Peptide Letters
Xiang Zhou, Lan Jin

Abstract

Alzheimer's disease (AD) is a serious neurodegenerative disorder. β-amyloid peptide (Aβ) aggregation is believed to be the major cause of the disease. The process of Aβ aggregation can be enhanced by sulfated glycosaminoglycans. However, cell experiments have shown that sulfated glycosaminoglycan oligosaccharides or analogues may have significant neuroprotective properties and could inhibit the aggregation by competitive inhibition. The length and species of oligosaccharides or analogues can inhibit the toxicity of Aβ by inducing conformational changes of proteins in different manners. This review presents the conformational changes of Aβ in the presence of glycosaminoglycan, glycosaminoglycan oligosaccharides and analogues. The review might be helpful to comprehend the mechanism of β-amyloid fibrillations and the aggregation process.

Citations


❮ Previous
Next ❯

Related Concepts

Related Feeds

Alzheimer's Disease: Amyloid Beta

Alzheimer's disease is a neurodegenerative disease associated with the accumulation of amyloid plaques in the brain; these plaques are comprised of amyloid beta deposits. Here is the latest research in this field.

Alzheimer's Disease: APP

Amyloid precursor protein (APP) proteolysis is critical for the development of Alzheimer's disease, a neurodegenerative disease associated with accumulation of amyloid plaques in the brain. Here is the latest research on APP and Alzheimer's disease.